Experienced in Upper Tract Urothelial Carcinoma (UTUC)

Jean-baptiste B. Lattouf

2900 Edouard Montpetit Blvd, 
Montreal, QC, CA 
Experienced in Upper Tract Urothelial Carcinoma (UTUC)
2900 Edouard Montpetit Blvd, 
Montreal, QC, CA 
OverviewLocationsClinical Research

Overview

Jean-baptiste Lattouf practices in Montreal, Canada. Mr. Lattouf is rated as an Experienced expert by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Renal Cell Carcinoma (RCC), Bladder Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.

His clinical research consists of co-authoring 102 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Upper Tract Urothelial Carcinoma (UTUC).

Gender
Male

Locations

2900 Edouard Montpetit Blvd, Montreal, QC, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate
Study Phase: Phase 2
View 1 Less Clinical Trial

102 Total Publications

Comparison of 90-day morbidity and mortality between ileal conduit and orthotopic neobladder following radical cystectomy in a large multi-institutional database: The Canadian CBCIS experience.
Comparison of 90-day morbidity and mortality between ileal conduit and orthotopic neobladder following radical cystectomy in a large multi-institutional database: The Canadian CBCIS experience.
Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada
Published: October 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lattouf's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile